Vascular Biogenics — Notable Labs — Investor Presentation (May 2024)
33 slides from Vascular Biogenics's investor presentation, May 6, 2024
Slide 1: Propelling the Right Drug to the Right Patient
Propelling the Right Drug to the Right Patient
Slide 2: Notable
KS Notable Enhancing the predictability of clinical response, we aim to develop treatments with better patient outcomes and reduced development risk, time, and cost
Slide 3: Disclaimer
Disclaimer Forward Looking Statements: This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable Labs, Ltd’s (“Notabl
Slide 4: Why Notable
Why Notable Notable is a clinical-stage oncology predictive therapeutics company with a novel responder-focused approach to drug development + Predictive medicine platform employs proprietary technology measuring functional cell response to treatment on a patient’s cancer sample without regard to ge
Slide 5: We Aim to Deliver Better and More Predictable Outcomes for Patients
We Aim to Deliver Better and More Predictable Outcomes for Patients Precision Medicine (one-dimensional) * Targets genomic mutations * Only 15% cancer patients carry actionable mutations * Response rate often low (considers only genetic mutations) Complete Response Rate (comp Example: R/R AML Bs Not
Slide 6: Bypassing Years and Millions of Dollars in Drug Development
Bypassing Years and Millions of Dollars in Drug Development Standard Model: From Discovery to Phase 3 — Takes an average of 15 years and $2.5 billion/drug Phase inpredicted Treatment responders New Patent Life Notable Model: Propel Advanced-Stage Drugs Over Finish Line — Bypass years of risk and mil
Slide 7: Acute Myeloid Leukemia (AML) is an Urgent Unmet Need
Acute Myeloid Leukemia (AML) is an Urgent Unmet Need * In 2024: there will be an estimated 20,800 cases of AML in adult: 1,220 deaths, mostly in adults (American Cancer Society’) o Average age at diagnosis 68 years + Recent approval of venetoclax/hypomethylating agents (ven/hma) have improved surviv
Slide 8: Volasertib: Background
Volasertib: Background + Extensively studied in solid and liquid tumors (AML) * Developed through Phase 3 in de novo AML by Boehringer Ingelheim (Bl) in over 1,400 patients * Volasertib/LDAC (low dose ara-c) Phase 2 front line AML trial achieved significantly higher response rate (31.0% CR + CRi) an
Slide 9: Predictive Medicine Platform
= Notable Predictive Medicine Platform
Slide 10: Genomics-Based Precision Medicines are Limited
Genomics-Based Precision Medicines are Limited Mutations ly Need an Approach That Goes Beyond Gen: Less than 15% of cancer patients? carry a known actionable genetic marker, and thus can benefit from traditional precision medicines In many clinical settings, genomics-based precision medicines delive
Slide 11: Notable's Predictive Medicine Platform
Notable’s Predictive Medicine Platform g Response Wi ally Actionable Timeframe and Without Regard to Genomic Data Patient Sample Predicted Responders Clinical Responders fo to to to te to to toto t Drug Treatment Predicted Non-Responders € Response Prediction Results in Seven Days or Less > aS Notab
Slide 12: Predictive Medicine Merges Biology and Advanced Technology
Predictive Medicine Merges Biology and Advanced Technology pope hon : Fresh Patient Sample ‘Multiple Readouts Includes Cancer and Immune Cells Biosimulation Assay at the Single Cell Level Patient Response Prediction Microenvironment Parameters Dying (Apoptosis) Dead Media Components Ojtkines/GrowthF
Slide 13: University: Clinical Validation Trial
University: Clinical Validation Trial S Patient Samples Demonstrate Patient-Specific Responses to Ex Vivo Drug Sensitivity Screenin; 54 Unique AML/MDS Patients Patients Screened Against 74 Compounds and 36 Drug Combinations 21 Patients Treated With Screened Compounds 11 Predicted Responders 10 Predi
Slide 14: All Platform-Predicted Responders Clinically Responded to Their Actual Treatment
All Platform-Predicted Responders Clinically Responded to Their Actual Treatment Myelodysplastic Syndromes, MDS 100%! (n 1) inical Validation Trial with Stanford: Results of the 21 Patients Treated with Platform-Screened Compounds? Predicted Non-Responders é Clinical Non-Responders Bs Notable e odod
Slide 15: 97% Predictive Precision Across Four Clinical Validation Trials
97% Predictive Precision Across Four Clinical Validation Trials @ Clinical Non-Responder @ Clinical Responder Predicted Responders 100%" (n=10) v \e soot : Stanford Univesity MD Anderson Cancer Cater Teyas Children’s Hospital ‘Myelodysplastic Syndromes, MDS Kota Riyal ace, Pediatric AML Dnoanavpnyai
Slide 16: Volasertib Predictive Performance Further De-Risks Program
Volasertib g Predictive Performance Further De-Risks Prog Volasertib Dose-Response 5 2 ® & Notable Score g ° a 02 Highly sensitive patients + | | 0.0 SS Coasec® ra 2 5 Ex Vivo Resistant Fraction — De Novo 0.2 — RR 0.0 —_Not Specified Disease State 0 2 2 0 10° 10) 10: @ De Novo No Volasertib Volasert
Slide 17: Volasertib: Flexible Threshold to Increase Response Rate
Volasertib: Flexible Threshold to Increase Response Rate Enrichment of Responders with Pre Selection Threshold Non- Responders § a 50% - ae <a ee ee = 3 = Non- 7 Responders J & X% - See -=——=—=— => --- Responders Responders Responders Response Rate= X% = 2X% = 100% Presented at AACR 2024, San Diego,
Slide 18: Volasertib Lead Candidate
= Notable Volasertib Lead Candidate
Slide 19: Volasertib: PLK1 Plays a Central Role in Leukemia and Other Cancers
Volasertib: PLK1 Plays a Central Role in Leukemia and Other Cancers Mechanism of Action Demonstrated Over-Expression Prometaphase * Polo-like kinase 1 Centrosome (PLK1) plays a central role in cancer cell proliferation * PLK1 over-expression has been found in a variety a of human cancers and “aeccca
Slide 20: Boehringer Ingelheim Volasertib Front Line AML Clinical Trials
Boehringer Ingelheim Volasertib Front Line AML Clinical Trials 753 Unique AML Patients across both trials a Treatment Patients were treated with LDAC+Vol Complete Response (CR) 6.7%(3) 14.3% (6) 12.2% (27) 15.1% (67) oe? cri 6.76(3) 16.7%(7) 5.0% (12) 12.6% (56) Overall ResponseRate (CR + Cr) 133% (
Slide 21: Volasertib Phase 2 and Phase 3 Trials: Survival Curves
Volasertib Phase 2 and Phase 3 Trials: Survival Curves Phase 2 Overall Survival? = woaan os — wre Temorte 05% 6.32110) = = LDAC + volasertib 9.8 months (95% Ci, 3.2-22.6) E% HA 0.54 (95% C1, 029-102) i 70: 2 6 go f° pe § 2 » o+ Tiotvewmnnenn mon mw sot Time ments) ‘ba pew ww wr 4 4s 221413 008 Dacro
Slide 22: Notable's Phase 2 Trial Overview
= Notable Notable’s Phase 2 Trial Overview
Slide 23: Volasertib: Notable's De-Risked Development Strategy
Volasertib: Notable’s De-Risked Development Strategy * Entering Phase 2 trial in R/R AML; design takes Phase 2 Trial Has Two Parts advantage of extensive BI post-hoc analysis * Dose optimization 6-12 patient lead-in to assess © Improves upon BI trials and further enhanced by using safety/tolerabilit
Slide 24: Phase 2 Design: Parts One and Two, Schedules A and B
lasertib* Phase 2 Design: Parts One and Two, Schedules A and B Part One (Unselected) Part 2 (Selected) une A+: 230 mg/m2 <1 DIT (in first 6) 200 mg/m2 -—_—_—_—_—___—_——>} RP2D mg/m2 Si A-1; 170 mg/m2 *in combination with decitabine, 20mg/m? days 1-5, q28 day cycles Bs Notable 2
Slide 25: The Phase 2 Key Criteria-Relapse/Refractory AML
The Phase 2 Key Criteria-Relapse/Refractory AML * Morphologically documented de novo or secondary/therapy-related AML or myelodysplastic syndromes (MDS)/AML, excluding participants with acute promyelocytic leukemia (APL) ¢ Participants’ disease must have failed treatment with or been intolerant to p
Slide 26: Volasertib Phase 2 Trial: Near-Term Inflection Points
Volasertib Phase 2 Trial: Near-Term Inflection Points v FDA Clearance Lead-In Data Continuous Data Read-Out First Site Initiated Predictive Selection Starts > x Qi 2024 922024 => Q3 2024 42024 «> Qi 2025 Q2 2025 Wie-)}> Bs Notable 26
Slide 27: Volasertib: Opportunities Beyond R/R AML
Volasertib: Opportunities Beyond R/R AML patients Potential to expand to first line AML in predicted-to- respond patient population © Establish platform as a screen for patients likely to respond to volasertib versus venetoclax based therapies © ORR for venetoclax based therapies is about 60-70% (VI
Slide 28: Corporate Summary and Intellectual Property
= Notable Corporate Summary and Intellectual Property
Slide 29: Notable Business Model
Notable Business Model Predict Clinical Responders Through the Notable Platform. Propel Advanced-Stage Drugs over the Finish Line llc iat Biology and Technology + Identifies patients most likely to respond to a treatment (no need for genetic markers, e.g. next generation sequencing) + Measures multi
Slide 30: Intellectual Property
Intellectual Property * In-licensed BI portfolio. * Currently protected via trade secret © 23 issued patents across API, formulation, method of use, * Parsing of knowledge across scientific, engineering and method of manufacture data teams API Loss of Exclusivity = 2027 ° y * Drug-specific method fi
Slide 31: Business Case for Notable Therapeutics and Potential Future Direction
Business Case for Notable Therapeutics and Potential Future Direction * Volasertib Therapeutic + Predicted Responder Companion Diagnostic © Advance volasertib program in predicted responders with relapse/refractory AML © Expand Volasertib program to frontline AML (predicted non-responders to standar
Slide 32: Executive Leadership
Executive Leadership Thomas Bock, M.D., MBA Chief Executive Officer Chief Executive Officer | HeritX SVP and Global Medical Head | Alexion VP and Global Medical Head | Celgene aS Notable Joseph Wagner, Ph.D. Chief Scientific Officer President and Chief Executive Officer | BriaCell Therapeutics Corp
Slide 33: Board of Directors
Board of Directors VSIsaes Tuomo Pasi Thomas Graney Thomas Dubin Michele Galen Michael Rice Peter Feinberg Thomas Bock Chair Chair Audit Committee Chair Compensation _ Director Director Director Chief Executive Officer, EVP, Commercial| Chief Executive officer | Commuter Chief Communication Founding